Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
